Artificial protein cages have potential as programmable, protective carriers of fragile macromolecules to cells. While natural cages and VLPs have been extensively exploited, the use of artificial cages to deliver active proteins to cells has not yet been shown. TRAP-cage is an artificial protein cage with an unusual geometry and extremely high stability, which can be triggered to break apart in the presence of cellular reducing agents. Here, we demonstrate that TRAP-cage can be filled with a protein cargo and decorated with a cell-penetrating peptide, allowing it to enter cells. Tracking of both the TRAP-cage and the cargo shows that the protein of interest can be successfully delivered intracellularly in the active form. These results provide a valuable proof of concept for the further development of TRAP-cage as a delivery platform.
Artificial protein cages have potential as programmable, protective carriers of fragile macromolecules to cells. While natural cages and VLPs have been extensively exploited, the use of artificial cages to deliver active proteins to cells has not yet been shown. TRAP-cage is an artificial protein cage with an unusual geometry and extremely high stability, which can be triggered to break apart in the presence of cellular reducing agents. Here, we demonstrate that TRAP-cage can be filled with a protein cargo and decorated with a cell-penetrating peptide, allowing it to enter cells. Tracking of both the TRAP-cage and the cargo shows that the protein of interest can be successfully delivered intracellularly in the active form. These results provide a valuable proof of concept for the further development of TRAP-cage as a delivery platform.
Transport of molecular
cargos to cells is desirable for a range
of applications including delivery of drugs, genetic material, or
enzymes. A number of nanoparticles have been employed to achieve this
including liposomes,[1] virus-like particles,[2] nonviral protein cages,[3] DNA origami cages,[4,5] and inorganic nanoparticles.[6] Protein cages are a promising approach as demonstrated
by viruses in nature which are able to deliver genetic material to
cells, often with high effectiveness and specificity. Adenoviruses,
for example, are highly efficient and bind quite specifically to the
CAR receptor.[7]Artificial protein
cages are constructed by proteins which do not
naturally form cage structures and in which interactions between constituent
proteins are modified to promote their assembly. The advantage of
using such an approach is that the resulting cages can be given properties
and capabilities that may not be available or feasible in naturally
occurring forms. This includes triggerable assembly,[8,9] which allows substituent proteins to be expressed as relatively
small individual subunits with/without cargos, thus circumventing
possible production problems associated with large complex formation
in the cell. Artificial cages also allow other features such as geometries
not seen in natural cages,[8] which widens
the possible library of building blocks, and replacement of enhancement
of protein–protein interactions with other interactions, leading
to control of disassembly.[8,10] To date, a number of
artificial protein cages have been produced including tandem fusions
of proteins with two- and threefold rotational symmetries able to
form a 12-subunit tetrahedral cage,[11−13] a nanocube structure
of 24 subunits with an octahedral symmetry,[14] a 60-subunit icosahedral cage structure that self-assembles from
trimeric protein building blocks,[15] and
co-assembling, two-component 120-subunit icosahedral protein complexes
comparable to those of small viral capsids[9] and designed peptides able to form networks that close to form cages.[16] Several examples exist where artificial protein
cages have been filled with various cargos including siRNA,[17,18] mRNA,[18,19] and fluorescent dyes.[10,20] However, only a handful of cases have demonstrated delivery of cargos
to cells by artificial cages.[17,20,21] To the best of our knowledge, delivery of protein cargos to cells
mediated by artificial protein cages (as opposed to natural cages)
has not previously been demonstrated. In this work, we show for the
first time that an artificial protein cage is capable of delivering
a functional protein cargo to the cell interior.We previously
produced an artificial protein cage using a building
block consisting of the naturally occurring ring-shaped protein, TRAP
(trp RNA-binding attenuation protein), referred to as TRAP-cage (Figure a).[8,22,23] In nature, TRAP is involved in
control of tryptophan synthesis and has been well characterized structurally
and biochemically.[24−27] It has also been used as a versatile building block in bionanoscience.[28−30] TRAP-cage consists of 24 TRAP rings, forming an approximately 22
nm-diameter, 2.2 MDa hollow sphere with a lumen roughly 16 nm in diameter.
Each TRAP ring in the cage is bound to five TRAP ring neighbors, and
the structure contains six square holes approximately 4 nm in diameter.
Unusually, compared to other natural and most artificial cages, the
ring subunits in the cage are held together not by a network of protein–protein
interactions. Instead, single gold(I) ions bridge opposing thiols
of the cysteine residues between rings in proteins where the naturally
occurring lysine at position 35 is replaced with cysteine. The cysteines
of 10 of the 11 monomers of each ring in the cage are bridged in this
way with those of the eleventh remaining unbridged and available to
react, for example, with maleimide-labeled dyes. As the constituent
TRAP ring is made from 11 monomers, it approximates a hendecagon,
which would not be expected to assemble to form a regular-faced convex
polyhedron. However, by assembling into an approximation of an Archimedean
solid (a snub cube) and allowing for small amounts of deviation/flexibility,
an “almost regular” TRAP-cage can form.[8]
Figure 1
TRAP-cage protein. (a) Structure of TRAP-cage (PDB:6RVV) with each TRAP-ring
shown in a different color. Gold atoms are shown as yellow spheres.
(b) Surface representation of the TRAP-cage exterior (left) and interior
(right) colored by charge distribution. (c) Surface view of a single
TRAP-ring with the face that points into the interior cavity shown,
colored according to the charge. (d) Negatively supercharged GFP(-21)
shown in cartoon representation (left) and surface view colored according
to charge (right). (e) Scheme of TRAP-cage encapsulation with GFP(-21)
and external modifications with Alexa-647 dye and PTD4 peptide.
TRAP-cage protein. (a) Structure of TRAP-cage (PDB:6RVV) with each TRAP-ring
shown in a different color. Gold atoms are shown as yellow spheres.
(b) Surface representation of the TRAP-cage exterior (left) and interior
(right) colored by charge distribution. (c) Surface view of a single
TRAP-ring with the face that points into the interior cavity shown,
colored according to the charge. (d) Negatively supercharged GFP(-21)
shown in cartoon representation (left) and surface view colored according
to charge (right). (e) Scheme of TRAP-cage encapsulation with GFP(-21)
and external modifications with Alexa-647 dye and PTD4 peptide.TRAP-cage is extremely stable and able to survive
temperatures
of 95 °C for at least 3 h and high levels of denaturing agents
such as 7 M urea.[8] Despite this high stability,
TRAP-cage breaks apart readily in the presence of low concentrations
of reducing agents including the cellular reducing agent glutathione.[8] This feature raises the prospect that the TRAP-cage
may have utility as a system for delivering cargos to cells, as it
can be expected to retain its structure, protecting the cargo until
entering cells where intracellular reducing agents will result in
disassembly and subsequent cargo release.Here, we show that
TRAP-cage can be deliberately filled with a
protein cargo, and we use a negatively supercharged variant of green
fluorescent protein, GFP(-21), as an exemplar molecule. Furthermore,
we show that TRAP-cage can be used to deliver such cargos to the interiors
of human cells. This cell penetration is itself controllable, as it
only occurs if the surface of TRAP-cage is modified, for example,
by cell-penetrating peptide. The results are a first step toward development
of TRAP-cage as a potentially useful tool for delivering medically
relevant cargos to cells and more generally demonstrate the potential
for artificial protein cage systems as therapeutic agents.
Materials and Methods
Production and Purification
of TRAP-Cage Filled with GFP(-21)
TRAP-cage (TRAP monomer
sequence: MYTNSDFVVIKALEDGVNVIGLTRGADTRFHH-SEKLDKGEVLIAQFTEHTSAIKVRGKAYIQTRHGVIESEGKK)
production and purification were performed as described previously.[8] Supercharged (-21) His-tagged GFP protein (MGHHHHHHGSACELMVSKGEELFTGVVPILVELDGDVNGHEFSVRGEGEGDATEGELTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHDVYITADKQENGIKAEFEIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDDHYLSTESALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK[31]) was expressed from pET28a encoding the GFP
gene and produced in BL21(DE3) cells. The protein was purified using
Ni-NTA. Briefly, cells were lysed by sonication at 4 °C in 50
mM Tris-HCl, pH 7.9, 150 mM NaCl, 5 mM MgCl2, and 5 mM
CaCl2, in the presence of protease inhibitors (Thermo Fisher
Scientific), and lysates were centrifuged at 20 000 g for 0.5 h at 4 °C. The supernatant was incubated with agarose
beads coupled with Ni2+-bound nitrilotriacetic acid (His-Pur
Ni-NTA, Thermo Fisher Scientific) pre-equilibrated in 50 mM Tris,
pH 7.9, 150 mM NaCl, and 20 mM imidazole (buffer A). After three washes
of the resin (with buffer A), the protein was eluted with 50 mM Tris,
pH 7.9, 150 mM NaCl, and 300 mM imidazole (buffer B). Fractions containing
His-tagged GFP(-21) were pooled and subjected to size exclusion chromatography
on a HiLoad 26/600 Superdex 200 pg column (GE Healthcare) in 50 mM
Tris-HCl, pH 7.9, and 150 mM NaCl at room temperature. Protein concentrations
were measured using a Nanodrop spectrophotometer using a wavelength
of 280 nm.GFP encapsulation was conducted by mixing equal volumes
of 100 μM negatively supercharged (-21) His-tagged GFP with
1 μM pre-formed TRAP-cage incubated overnight in 50 mM Tris
and 150 mM NaCl (pH 7.9). Purification of TRAP loaded with GFP(-21)
was carried out by size exclusion chromatography using a Superose
6 Increase 10/300 column (GE Healthcare) in 50 mM HEPES, pH 7.5, and
150 mM NaCl. Fractions containing TRAP-cage were collected and analyzed
by native PAGE using 3–12% native Bis-Tris gels (Life Technologies)
followed by fluorescence detection using a Chemidoc detector (BioRad)
with excitation at 488 nm.
Ni-NTA “Pull Down”
Samples of purified
TRAP-cage filled with His-tagged GFP(-21) protein were divided into
two portions and incubated under reducing (1 mM TCEP) or nonreducing
(no TCEP) conditions. Next, samples were passed through a Ni-NTA resin
(Thermo Fisher Scientific) under gravitational flow, in which 100
μL of each sample was introduced onto 50 μL of the resin
equilibrated with buffer A. Three samples were collected: (i) flow
through, (ii) wash with buffer A, and (iii) elution with buffer B.
Samples were analyzed by native PAGE, followed by fluorescence detection
(excitation at 488 nm, Chemidoc, BioRad) and western blot. For the
SDS-PAGE and western blot, samples collected from the Ni-NTA pull-down
assay were denatured by addition of TCEP (final concentration 0.1
mM) and boiling for 15 min followed by separation via Tris/Glycine
gel electrophoresis. Gels were then subjected to electrotransfer (2
h, 90 V) in 25 mM Tris, 192 mM glycine, and 20% methanol buffer onto
an activated PVDF membrane. The membrane was blocked with 5% skimmed
milk in Tris-buffered saline supplemented with 0.05% Tween 20 (TBS-T),
followed by 1.5 h of incubation with the mouse monoclonal anti-GFP
antibody (1:2500; St. John’s Laboratories, UK) and anti-mouse
(1:5000, Thermo Fisher Scientific) secondary antibody conjugated with
horse radish peroxidase. The signal was developed using a Pierce ECL
western blotting substrate (Thermo Fisher Scientific) and visualized
in a BioRad Chemidoc detector.
TRAP-Cage Labeling with
Alexa-647 and Decoration with Cell-Penetrating
Peptide
Alexa Fluor-647 C2 maleimide fluorescent dye (Alexa-647,
Thermo Fisher Scientific) and cell-penetrating PTD4 peptide were conjugated
to the TRAP-cage filled with GFP(-21) via crosslinking reactions with
cysteines and lysines present in the TRAP protein.To achieve
fluorescent labeling, TRAP-cage carrying GFP(-21) (300 μL, 16
nM) was mixed with a Alexa-647 C2 maleimide dye (50 μL, 1 μM);
the reaction was conducted in 50 mM HEPES with 150 mM NaCl, pH 7.5,
for 2.5 h at room temperature with continuous stirring at 450 rpm.
The optimal interaction ratio of maleimide-conjugated Alexa-647 to
TRAP-cage was assessed by titration (Figure S3a). Briefly, aliquots of TRAP-cage loaded with GFP(-21) (11.36 nM)
were mixed with maleimide-conjugated Alexa-647 at concentrations ranging
from 0.1 to 100 μM. Samples were then separated by native gel
electrophoresis and visualized by fluorescence detection in a Chemidoc
system, with excitation at 647 nm. Reactions where no free Alexa-647
is present in the sample and no GFP(-21) interference with the Alexa-647
signal is observed were considered to possess optimal decoration conditions
and used in further experiments. The yield of TRAP-cage labeling with
Alexa-647 was quantified using fluorescence detection of the labeled
TRAP protein.Additionally, to rule out the possibility of direct
GFP(-21) labeling
by Alexa-647, TRAP-cage loaded with GFP(-21) with and without Alexa-647
labeling was subjected to denaturing gel separation and western blotting
followed by detection with the anti-GFP antibody.For the cell-penetrating
peptide decoration, PTD4 peptide (50 μL,
0.5 mM) was mixed with 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC, 10 μL, 83 mM) and N-hydroxysuccinimide
(NHS, 10 μl, 435 mM), all reagents dissolved in ddH2O. Subsequently, an excess of activated PTD4 peptides was added to
TRAP-cage filled with GFP(-21) and labeled with Alexa-647 and incubated
for 2.5 h at room temperature, with continuous stirring at 450 rpm.
The reaction was stopped by addition of 5 μL of 200 mM Tris-HCl,
pH 7.5. The conjugation efficiency was verified by native PAGE, fluorescent
gel imaging, and HPLC analysis.
Electron Microscopy
TRAP-cage filled with GFP(-21),
TRAP-cage filled with GFP(-21) and labeled with Alexa-647, and TRAP-cage
filled with GFP(-21) and fully decorated were imaged using transmission
electron microscopy (TEM). Samples were typically diluted to a final
protein concentration of 0.025 mg/mL and centrifuged at 10,000g for 5 min at room temperature, and the supernatant was
applied onto hydrophilized carbon-coated copper grids (STEM Co.) Samples
were then negatively stained with 3% phosphotungstic acid, pH 8, and
visualized using a JEOL JEM-2100 instrument operated at 80 kV.
Flow Cytometry
For TRAP-cage internalization experiments,
MCF-7 and HeLa cells were seeded into 12-well plates (VWR) in 800
μL of DMEM medium with 10% FBS at a density of 2.5 × 105 per well and cultured for further 16 h prior to the experiments.
Cells were then incubated with 50 μg (6 nM) of TRAP-cage filled
with the cargo, labeled with Alexa-647 only, or decorated with Alexa-647
and PTD4 peptide in 50 mM HEPES with 150 mM NaCl, pH 7.5, supplemented
with 10% FBS for 15 min, 2, and 4 h at 37 °C, 5% CO2. After the incubation, cells were washed three times for 5 min with
phosphate-buffered saline (PBS) (EURx), harvested with trypsin (1
mg/mL), and centrifuged at 150g for 5 min. Subsequently,
cells were washed thrice in PBS by centrifugation (150g for 3 min) and re-suspended in 0.5 mL of PBS. Cells were run in
a Navios flow cytometer (Beckman Coulter), and the fluorescence of
12,000 cells was collected for each sample. Untreated cells and cells
treated with TRAP-cage filled with cargo and labeled with Alexa-647
only were used as negative controls. Obtained data for three independent
experiments were analyzed with Kaluza software (Beckman Coulter).
The percentage of Alexa-647/GFP(-21) positive cells and median fluorescence
intensity was determined for each sample.
Laser Scanning Confocal
Microscopy
For fluorescent
laser scanning confocal microscopy observations, cells were grown
on 15 mm glass cover slips plated into 12-well plates (2.5 ×
105 per well in 800 μL of DMEM medium with 10% FBS)
and further stimulated with 50 μg (6 nM) of TRAP-cage filled
with the cargo, labeled with Alexa-647 only, or decorated with Alexa-647
and PTD4 peptide in 50 mM HEPES with 150 mM NaCl, pH 7.5, supplemented
with 10% FBS for 4 h at 37 °C and 5% CO2. Next, cells
were washed with PBS (three times for 5 min), fixed with 4% paraformaldehyde
solution (15 min, at room temperature), and permeabilized with 0.5%
Triton-X100 in PBS (7 min, at room temperature). Actin filaments were
stained with phalloidin conjugated to Alexa-568 in PBS (1:300, Thermo
Fisher Scientific, 1.5 h, at room temperature). Cover slips were then
mounted on slides using Prolong Diamond medium with DAPI (Thermo Fisher
Scientific). Fluorescent images were acquired under an Axio Observer.Z1
inverted microscope (Carl Zeiss, Jena, Germany), equipped with the
LSM 880 confocal module with a 63× oil immersion objective. Images
were processed using ImageJ 1.47v (National Institute of Health).
Results and Discussion
Filling of TRAP-Cage
To fill TRAP-cage,
we took advantage
of the fact that the only significant patch of positive charge on
the surface of the TRAP ring lies on the face lining the interior
of the cage (Figure b,c). In principle, this could allow capture of negatively charged
cargos via electrostatic interactions as has been demonstrated for
other protein cages.[32−36] The fact that the constituent TRAP rings do not assemble into TRAP-cage
until the addition of gold(I)[8] means that
protein cargos below approximately 4 nm (the size of the fourfold
holes in TRAP-cage[8]) have two possible
routes for encapsulation—they may bind to TRAP rings prior
to assembly or they may be added after TRAP-cage formation and allowed
to diffuse into the cage through the fourfold holes. We chose negatively
supercharged GFP(-21) as a model cargo (Figure d). This cylindrically shaped protein has
a diameter of approximately 2.4 nm and is therefore expected to be
able to diffuse into the assembled TRAP-cage (Figure e). His-tagged GFP(-21) was mixed with TRAP-cages
and incubated overnight, followed by size exclusion chromatography
purification for removal of remaining free GFP(-21). It was found
that the two proteins associated as shown by co-migration of fluorescence
signals on native gels (Figure a). To verify whether His-tagged GFP(-21) is inside the TRAP-cage
and not bound to its exterior, we conducted a pull-down assay using
Ni-NTA affinity chromatography, followed by western blot analysis.
The observation that the GFP(-21) associated with TRAP-cage did not
bind to the Ni-NTA column suggested successful encapsulation, making
the His-tag inaccessible. This was further supported by a pull-down
assay, which showed that the associated GFP(-21) was only available
to interact with a Ni-NTA column after the cage was dissociated by
the addition of a reducing agent (Figure b). These results strongly suggest encapsulation
of GFP(-21) in TRAP-cage in either full or partial modes (partial
encapsulation being the case where the GFP(-21) “plugs”
the holes in TRAP-cage with the His-tags pointing to the interior).
The number of GFP(-21) per cage was approximately 0.3 (Figure S1), similar to but lower than the range
found in a number of other filled protein cages,[36−38] although some
have shown considerably greater numbers of cargos.[39] Where the magnitude of charge complementarity is lower,
a low cargo loading is expected, and while we have used a supercharged
GFP, the cage interior bears only small patches of positive charges
associated with the wild-type protein, likely accounting for the relatively
low loading efficiency, which could, in future work, be addressed
by modifying TRAP-cage further, such that it carries a higher density
of positive charges within the cage interior. Alternatively, different
methods of cargo capture (such as covalent attachment) could be explored,
as described for other protein cages.[39,40]
Figure 2
Filling and
decoration of TRAP-cage. (a) Native PAGE gels showing
purified TRAP-cage incubated with His-tagged GFP(-21) after passing
through a Ni-NTA column in the absence (−TCEP) or presence
(+TCEP) of TCEP. Lane 1: GFP(-21) positive control; 2: molecular weight
marker for native PAGE; 3: empty TRAP-cage; 4: input [TRAP-cage with
GFP(-21)]; 5 and 8: flow through; 6 and 9: wash; and 7 and 10: elution.
Collected fractions were stained for protein (left) or analyzed by
fluorescence detection (right, exct. 488 nm). The GFP signal visible
in lane 10 of the right-side gel likely reflects GFP still bound to
a TRAP ring. (b) Western blot of the gel in (a): collected fractions
were subjected to SDS-PAGE followed by western blot with anti-GFP
detection. Lane 1: GFP(-21) positive control; 2: molecular weight
marker for SDS-PAGE; 3: empty TRAP-cage; 4: input (TRAP-cage with
GFP); 5 and 8: flow through; 6 and 9: wash; and 7 and 10: elution.
(c) Native PAGE gels showing encapsulation of GFP(-21) by unmodified
TRAP-cage or TRAP-cage externally modified with Alexa-647 and PTD4.
Lane 1: TRAP-cage with GFP(-21); 2: TRAP-cage with GFP(-21) decorated
with Alexa-647; 3: TRAP-cage with GFP(-21) decorated with Alexa-647
and PTD4; and 4: molecular weight marker for native PAGE. Gels were
stained for protein (upper panel) and analyzed by fluorescence detection
of GFP (middle panel, exct. 488 nm) and Alexa-647 (bottom panel, exct.
647). Gels were imaged using a Biorad Chemidoc detector. (d) Negative
stain TEM of TRAP-cage with GFP(-21) (left panel); TRAP-cage with
GFP(-21) decorated with Alexa-647 (middle panel); and TRAP-cage with
GFP(-21) decorated with Alexa-647 and PTD4 (right panel).
Filling and
decoration of TRAP-cage. (a) Native PAGE gels showing
purified TRAP-cage incubated with His-tagged GFP(-21) after passing
through a Ni-NTA column in the absence (−TCEP) or presence
(+TCEP) of TCEP. Lane 1: GFP(-21) positive control; 2: molecular weight
marker for native PAGE; 3: empty TRAP-cage; 4: input [TRAP-cage with
GFP(-21)]; 5 and 8: flow through; 6 and 9: wash; and 7 and 10: elution.
Collected fractions were stained for protein (left) or analyzed by
fluorescence detection (right, exct. 488 nm). The GFP signal visible
in lane 10 of the right-side gel likely reflects GFP still bound to
a TRAP ring. (b) Western blot of the gel in (a): collected fractions
were subjected to SDS-PAGE followed by western blot with anti-GFP
detection. Lane 1: GFP(-21) positive control; 2: molecular weight
marker for SDS-PAGE; 3: empty TRAP-cage; 4: input (TRAP-cage with
GFP); 5 and 8: flow through; 6 and 9: wash; and 7 and 10: elution.
(c) Native PAGE gels showing encapsulation of GFP(-21) by unmodified
TRAP-cage or TRAP-cage externally modified with Alexa-647 and PTD4.
Lane 1: TRAP-cage with GFP(-21); 2: TRAP-cage with GFP(-21) decorated
with Alexa-647; 3: TRAP-cage with GFP(-21) decorated with Alexa-647
and PTD4; and 4: molecular weight marker for native PAGE. Gels were
stained for protein (upper panel) and analyzed by fluorescence detection
of GFP (middle panel, exct. 488 nm) and Alexa-647 (bottom panel, exct.
647). Gels were imaged using a Biorad Chemidoc detector. (d) Negative
stain TEM of TRAP-cage with GFP(-21) (left panel); TRAP-cage with
GFP(-21) decorated with Alexa-647 (middle panel); and TRAP-cage with
GFP(-21) decorated with Alexa-647 and PTD4 (right panel).
Decoration of TRAP-Cage with a Fluorescent Dye and with Cell-Penetrating
Peptides
In order to be able to track TRAP-cage independently
from its cargo, we labeled it with the Alexa-647 fluorescent dye.
For this, we crosslinked the maleimide group on the dye with the 24
available cysteines lining the six 4 nm holes of TRAP-cage that are
not involved in ring–ring interactions. By titration, we established
the optimal amount of Alexa-647 to be added, this being the concentration
at which the TRAP-cage is readily labeled and no free dye is present
in the sample. It was assessed by native PAGE combined with fluorescent
measurements to detect both GFP(-21) and Alexa-647 (Figure S3a). The yield of TRAP-cage labeling with Alexa-647
was quantified using fluorescence detection of labeled TRAP-cage of
known concentration. The average number of Alexa-647 molecules bound
to TRAP-cage was estimated to be 2 (Figure S3b). Although the cargo GFP(-21) contains three cysteine residues,
control reactions showed no detectable labeling of GFP(-21) with Alexa-647
(Figure S3c).We aimed to modify
the TRAP-cage in order to promote its cell entry. For this, we chose
PTD4 (YARAAARQARA)—an optimized TAT-based cell-penetrating
peptide that shows a significantly improved ability to penetrate cell
membranes, being more amphipathic with a reduced number of arginines
and increased α-helical content.[41] A number of studies have shown that coating nanoparticles with PTD4
promotes cell penetration.[42,43] We attached the PTD4
derivative Ac-YARAAARQARAG to the amino groups on surface-exposed
lysines of TRAP-cage. Based on the known structure,[8] there are three such surface-exposed lysines per monomer
on TRAP-cage, potentially allowing 792 peptides to be attached per
cage. Calculations based on peptide peak areas from HPLC chromatograms
were used to determine the initial amount of peptide and remaining
amount after conjugation with TRAP-cage, indicating that 230 ±
22 PTD4 peptides are attached to one TRAP-cage (Figure S4b).In reactions optimized for Alexa-647 labeling,
we observed an increase
in the apparent molecular weight of TRAP-cage after reaction with
PTD4 (Figure c), as
visualized by native PAGE. Negative stain TEM confirmed that the modified
TRAP-cages retained their characteristic shape and size, being 22
nm in diameter (Figure d).
Stability of TRAP-Cage and Effect on Cell Viability
Before embarking on cell delivery tests, we first assessed whether
TRAP-cage was structurally stable, that is, did not disassemble under
cell culture conditions. Stability was checked at 37 °C and in
a 5% CO2 atmosphere in Dulbecco’s modified eagle
medium (DMEM) without or with fetal bovine serum (FBS) at various
concentrations. The results showed that the TRAP-cage structure is
stable in DMEM culture medium within 18 h of incubation at 37 °C
and 5% CO2 (Figure S5a).In order to determine the effect of TRAP-cage on cell viability,
alamarBlue assays were carried out. This test is based on the natural
ability of viable cells to convert resazurin, a blue and nonfluorescent
compound, into resofurin, a red and fluorescent molecule by mitochondrial
and other reducing enzymes.[44] Human cancer
cell lines MCF-7 and HeLa were incubated in the presence of TRAP-cage
and TRAP-cage filled with GFP(-21) and decorated with Alexa-647 and
PTD4 peptide. The number of cells, TRAP-cage dose, and stimulation
time used in cell viability tests correspond to the conditions under
which the internalization of the TRAP-cage experiments was performed.
Untreated cells were used as a control. The data showed that both
unmodified TRAP-cage and TRAP-cage filled with GFP(-21) and decorated
with Alexa-647 and PTD4 do not significantly affect the viability
of MCF-7 and HeLa cells for at least 4 h of incubation (Figure S5b).
Delivery of the Protein
Cargo to Cells
Delivery of
TRAP-cage to cells was studied using human cancer cell lines MCF-7
and HeLa. Cells were incubated for different time periods with the
purified TRAP-cages containing encapsulated GFP(-21) and labeled with
Alexa-647 only or with Alexa-647 and PTD4 and analyzed by flow cytometry.
The fluorescent signal due to both Alexa-647 and GFP(-21) increased
with prolonged incubation time in both cell lines treated with TRAP-cage
with GFP(-21) labeled with Alexa-647 and PTD4 peptide (Figure a,b). These results show that
external modification of TRAP-cages with cell-penetrating peptides
promotes their cell entry and effective cargo delivery. Interestingly,
this effect was more pronounced in the case of the MCF-7 cell line
compared to the HeLa cell line (Figure S6a,b).
Figure 3
Delivery of TRAP-cage carrying GFP(-21) to MCF-7 cells. (a) Representative
flow cytometry dot plots of MCF-7 cells after 4 h of treatment with
Alexa-647-labeled TRAP-cage carrying GFP(-21) [denoted as (TC + GFP)
+ Alexa-647] and TRAP-cage with GFP(-21) labeled with Alexa-647 and
PTD4 peptide [denoted as (TC + GFP) + Alexa-647 + PTD4] for 15 min,
2, and 4 h. The x-axis and the y-axis show the fluorescent intensities of GFP and Alexa-647, respectively.
Untreated cells were used as the negative control. (b) Median fluorescence
intensity of Alexa-647 and GFP positive cells treated with TRAP-cage
carrying GFP and decorated with Alexa-647 or decorated with both Alexa-647
and PTD4 after 15 min, 2, and 4 h of incubations. Data are normalized
to untreated cells and based on three independent experiments. Controls:
C1: untreated cells and C2: cells incubated with (TC + GFP) + Alexa-647.
(c) Confocal microscopy images of controls: untreated cells (first
row), cells after 4 h of treatment with TRAP-cage filled with GFP(-21)
labeled with Alexa-647 only (second row), TRAP-cage filled with GFP(-21)
and labeled with Alexa-647 and PTD4 (third row) with additional single
optical sections through the middle of the cell (fourth row). Actin
filaments were stained with phalloidin conjugated to Alexa-568, and
nuclei were stained with DAPI. Green channel: GFP; red channel: Alexa-647;
blue channel: DAPI; and gray channel: Alexa-568. Merge: overlay image
of red and green channels. Confocal images were taken at 63×;
scale bar: 10 μm.
Delivery of TRAP-cage carrying GFP(-21) to MCF-7 cells. (a) Representative
flow cytometry dot plots of MCF-7 cells after 4 h of treatment with
Alexa-647-labeled TRAP-cage carrying GFP(-21) [denoted as (TC + GFP)
+ Alexa-647] and TRAP-cage with GFP(-21) labeled with Alexa-647 and
PTD4 peptide [denoted as (TC + GFP) + Alexa-647 + PTD4] for 15 min,
2, and 4 h. The x-axis and the y-axis show the fluorescent intensities of GFP and Alexa-647, respectively.
Untreated cells were used as the negative control. (b) Median fluorescence
intensity of Alexa-647 and GFP positive cells treated with TRAP-cage
carrying GFP and decorated with Alexa-647 or decorated with both Alexa-647
and PTD4 after 15 min, 2, and 4 h of incubations. Data are normalized
to untreated cells and based on three independent experiments. Controls:
C1: untreated cells and C2: cells incubated with (TC + GFP) + Alexa-647.
(c) Confocal microscopy images of controls: untreated cells (first
row), cells after 4 h of treatment with TRAP-cage filled with GFP(-21)
labeled with Alexa-647 only (second row), TRAP-cage filled with GFP(-21)
and labeled with Alexa-647 and PTD4 (third row) with additional single
optical sections through the middle of the cell (fourth row). Actin
filaments were stained with phalloidin conjugated to Alexa-568, and
nuclei were stained with DAPI. Green channel: GFP; red channel: Alexa-647;
blue channel: DAPI; and gray channel: Alexa-568. Merge: overlay image
of red and green channels. Confocal images were taken at 63×;
scale bar: 10 μm.In order to discriminate
between fluorescent signals from TRAP-cages
which were internalized in the cells and those which were adsorbed
externally on the cell membrane, confocal microscopy was used. TRAP-cage
containing GFP(-21) and labeled with Alexa-647 but lacking PTD4 was
not observed in the cells. In contrast, TRAP-cage containing GFP(-21)
and decorated with PTD4 showed a clear signal in the cell interior
at 4 h after stimulation (Figures c and S6c).The demonstration
of delivery of the active protein cargo to cell
interiors via an artificial protein cage is of interest given the
small number of previous studies on artificial protein cage-mediated
delivery of cargos to cells demonstrated for nonprotein cargos. Notably,
Edwardson and co-workers showed that an artificial protein cage loaded
with siRNA can be taken up by different mammalian cells and can release
its cargo to induce RNAi and knockdown of target gene expression.[17] In this case, the high gene-silencing efficiency
together with low toxic effects indicated that a protein cage carrier
has potential as a therapeutic delivery system. Encapsulation of protein
cargos within artificial protein cages has previously been demonstrated
by Votteler and colleagues.[21] However,
these cages were not shown to be able to directly deliver their cargo
to cells. Instead, multiple copies of the cages themselves were used
as cargos within lipid envelopes made in cells and purified as enveloped
protein nanocages (EPNs), where the lipid envelope was derived from
the host cell membrane. The EPNs were able to deliver the cages, meaning
that entry to cells was achieved by the enveloping, host-derived membrane,
not the protein cage.
Intracellular Dynamics of TRAP-Cage
The high stability
of TRAP-cage coupled with its ability to break apart in the presence
of modest concentrations of cellular reducing agents suggests that
TRAP-cage in the cytoplasm should readily disassemble, releasing the
GFP(-21) cargo. As TRAP-cage and GFP(-21) possess discrete and trackable
signals, we hypothesized that cage disassembly and release of GFP(-21)
may be strongly inferred if the Alexa-647 and GFP(-21) signals became
non-colocalized after cell entry. To assess this possibility, we tracked
both signals over time after addition to MCF-7 and HeLa cancer cells.
Notably, in both cell lines tested, during the first 90 min of incubation,
TRAP-cage was mainly present at the cell boundaries, as indicated
by the strong localization of the Alexa-647 signal there, and the
GFP(-21) signal was barely detectable. However, after 3 h of incubation,
the TRAP-cage signal (Alexa-647) became weaker and appeared to be
distributed more evenly in the cell, whereas the GFP(-21) signal was
clearly detectable, likely due to its release from the TRAP-cages
(Figures and S7). While differentiating between intracellular
GFP(-21) in the cytoplasm and the endosome is challenging, evidence
supporting cytoplasmic localization comes from the lag observed in
the appearance of the GFP(-21) signal. IF GFP(-21) was localized in
the endosome, we would expect degradation to result in a decrease
rather than an increase in the signal over time.
Figure 4
Tracking TRAP-cage and
GFP(-21) in MCF-7 cells. Confocal microscopy
merged images of cells incubated with TRAP-cage carrying GFP(-21)
decorated with Alexa-647 and PTD4 and fixed at different time points.
Actin was stained with phalloidin conjugated to Alexa-568, whereas
DAPI was used for nuclear staining. Rectangular images beneath each
main image are representative orthogonal views in the yz axis. Confocal images were taken at 63×; scale bar: 10 μm.
Tracking TRAP-cage and
GFP(-21) in MCF-7 cells. Confocal microscopy
merged images of cells incubated with TRAP-cage carrying GFP(-21)
decorated with Alexa-647 and PTD4 and fixed at different time points.
Actin was stained with phalloidin conjugated to Alexa-568, whereas
DAPI was used for nuclear staining. Rectangular images beneath each
main image are representative orthogonal views in the yz axis. Confocal images were taken at 63×; scale bar: 10 μm.To further confirm that TRAP-cage with GFP(-21)
is successfully
delivered to the cell interior and the cargo is released, we performed
in-cell ELISA, where we detect GFP(-21) with a specific antibody,
at several time points. These results demonstrated that the longer
the cells were incubated with TRAP-cage filled with GFP(-21), the
more detectable the GFP(-21) signal, suggesting that the cargo protein
becomes more accessible for the antibody, that is, released or exposed
by cage opening (Figure S11).The
change in relative signal strengths of TRAP-cage-associated
Alexa-647 versus GFP(-21) once in the cell is suggestive of intracellular
break-up of the cage and release of the cargo. A possible explanation
is that when Alexa-647 and GFP(-21) are in close proximity to each
other due to association with TRAP-cage, the GFP(-21) fluorescence
may be decreased due to a (non-FRET) quenching effect from the dye.
Once GFP(-21) is released by TRAP-cage disassembly, average GFP(-21)
to Alexa-647 distances become larger, resulting in an increase in
the detected GFP(-21) fluorescence. This possibility is supported
by the observation that the signal from intracellular GFP(-21) is
visibly brighter when it is delivered using TRAP-cage lacking Alexa-647
(Figure S6). Given the relatively low occupancy
of GFP(-21) inside TRAP-cage and the fact that on average, each 24-ring
cage bears only two Alexa-647 dye molecules, cage disassembly could,
in principle, lead to separation of rings with electrostatically attached
GFP(-21) from Alexa-647 simply by virtue of the fact that the ring
to which GFP(-21) attached is not labeled with Alexa-647. For future
potential use, this is not necessarily problematic, depending on the
identity of the protein cargo, which will be active as long as any
binding/active site is accessible.
Conclusions
In
this work, we demonstrated that an artificial protein cage can
be used to deliberately encapsulate a protein cargo and deliver it
to cell interiors. Importantly, the protein cages employed either
in an unmodified form or externally decorated showed no significant
effects on cell viability.To achieve protein cage-encapsulated
protein delivery to cells,
we used our previously developed TRAP-cage[8] having positively charged patches on its interior, to capture negatively
supercharged GFP electrostatically through diffusion into the cage.
Attempts to deliver filled cages to cells showed no evidence of penetration
of TRAP-cages into cells if they were undecorated. In contrast, attachment
of the cell-penetrating peptide PTD4 to the exterior of TRAP-cages
resulted in significant penetration into cell interiors.Overall,
the work presented herein offers the first demonstration
of protein delivery to cells mediated with a prototype system employing
artificial protein cages (which we differentiate from engineered cages
by virtue of the fact that artificial cages are protein cages whose
constituent proteins do not naturally form a cage). An engineered
cage, by contrast, is an existing cage (natural or artificial) that
has been engineered, that is, altered to give it certain properties.
We demonstrated a relatively low cargo-filling efficiency, and in
the future study, this could be addressed by modifying TRAP-cage further
such that it carries a higher density of positive charge within the
cage interior. Alternatively, different methods of cargo capture (such
as covalent attachment) could be explored, as described for other
protein cages.[39,40] Additionally, we anticipate further
modification of TRAP-cage both to increase targeting specificity and
to extend the range and usefulness of the encapsulated cargo. Finally,
future studies will be required to pinpoint and track both the precise
intracellular location of TRAP-cages and their quaternary state.
Authors: Jordan M Fletcher; Robert L Harniman; Frederick R H Barnes; Aimee L Boyle; Andrew Collins; Judith Mantell; Thomas H Sharp; Massimo Antognozzi; Paula J Booth; Noah Linden; Mervyn J Miles; Richard B Sessions; Paul Verkade; Derek N Woolfson Journal: Science Date: 2013-04-11 Impact factor: 47.728
Authors: Masahiro Watanabe; Jonathan G Heddle; Kenichi Kikuchi; Satoru Unzai; Satoko Akashi; Sam-Yong Park; Jeremy R H Tame Journal: Proc Natl Acad Sci U S A Date: 2009-01-22 Impact factor: 11.205
Authors: Yang Hsia; Jacob B Bale; Shane Gonen; Dan Shi; William Sheffler; Kimberly K Fong; Una Nattermann; Chunfu Xu; Po-Ssu Huang; Rashmi Ravichandran; Sue Yi; Trisha N Davis; Tamir Gonen; Neil P King; David Baker Journal: Nature Date: 2016-06-15 Impact factor: 49.962
Authors: Jacob B Bale; Shane Gonen; Yuxi Liu; William Sheffler; Daniel Ellis; Chantz Thomas; Duilio Cascio; Todd O Yeates; Tamir Gonen; Neil P King; David Baker Journal: Science Date: 2016-07-22 Impact factor: 47.728